Search
Denileukin diftitox
go.drugbank.com/drugs/DB00004ApprovedInvestigationalapproved to treat a human disease in the US. … [A264344] In 2014, it was withdrawn voluntarily from the market due to manufacturing issues; however, the biologics license application (BLA) for denileukin diftitox was resubmitted, and it was approved
Synonyms: N-MET-187-HIS-388-ALA-1-388-TOXIN (CORYNEBACTERIUM DIPHTHERIAE C7) WITH 1-133-INTERLEUKIN 2, N-L-METHIONYL-387-L-HISTIDINE-388-L-ALANINE-1-388-TOXIN (CORYNEBACTERIUM DIPHTHERIAE STRAIN C7) (388->2') PROTEIN WITH 2-133-INTERLEUKIN 2 (HUMAN CLONE PTIL2-21A)Genistein
go.drugbank.com/drugs/DB01645InvestigationalIt has been determined to be the active ingredient in <I>Felmingia vestita</I>, which is a plant traditionally used against worms. … It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women [A14417].
Mixtures: OSMEGA 600 MG/400 IU/25 MG EFERVESAN TABLET, 30 ADET, CALCIDAY G 1200 MG/800 IU/50 MG EFERVESAN TABLET, 45 ADETCategories: Compounds used in a research, industrial, or household settingDimethyl fumarate
go.drugbank.com/drugs/DB08908ApprovedInvestigationalin response to oxidative stress. … [A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood.
Tislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy
Sarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationals Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients … dermatology-focused pharmaceutical company's presence in the United States [L4815].
Microcrystalline cellulose
go.drugbank.com/drugs/DB14158ApprovedInvestigationalA polysaccharide with glucose units linked as in CELLOBIOSE. It is the chief constituent of plant fibers, cotton being the purest natural form of the substance. … As a raw material, it forms the basis for many derivatives used in chromatography, ion exchange materials, explosives manufacturing, and pharmaceutical preparations.
Categories: Compounds used in a research, industrial, or household settingDimethyl sulfoxide
go.drugbank.com/drugs/DB01093ApprovedInvestigationalVet approvedA highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. … It is also used to protect tissue during cryopreservation. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.
Categories: Compounds used in a research, industrial, or household settingTrazodone
go.drugbank.com/drugs/DB00656ApprovedInvestigational[T646] It was initially granted FDA approval in 1981.[L3484] … [A181180] It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine
Phendimetrazine
go.drugbank.com/drugs/DB01579ApprovedIllicitPhendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.
Delgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigationalDelgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024. … [L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]